TCA Tanoira Cassagne advised Tecnovax as issuer, StoneX Securities as arranger and placement agent, and Nuevo Banco de Santa Fe as placement agent, in connection with the issuance of: (i) the series I class 1 Notes, for a nominal amount of AR$5,720,000,000, denominated and payable in Argentine Pesos, that will accrue interest at a floating rate equal to the TAMAR Rate plus 5.00% margin, maturing on January 13, 2028; and (ii) the series I class 2 Notes, for a nominal amount of US$1,128,069, denominated and payable in U.S. dollars in the Republic of Argentina, maturing on June 30, 2028, that will accrue interest at a fixed nominal annual rate of 6.48%; issued under the National Securities and Exchange Commission’s Automatic Public Offering Authorization Regime for its Medium Impact.
Tecnovax is a biotechnology company fully dedicated to the research, development, production and commercialization of innovative products for the prevention of infectious diseases in animal health. The company currently has four vaccine lines for the prevention of infectious diseases in ruminants, canines, felines and aquatic species, as well as a new equine line developed to address the outbreak of Equine Encephalomyelitis that emerged in late 2023.
Deal Counsel of the Transaction: TCA Tanoira Cassagne: Partners Alexia Rosenthal and Jaime Uranga and Associates Juan Manuel Simó, Stefanía Lo Valvo and Tobías Bonamico.
